Event context and recent stock move

BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, while longer term returns remain weaker.

The latest move sits against a mixed backdrop, with the share price down about 10% over the past three months and year to date, while the 1-year total shareholder return is also slightly negative. This pattern suggests recent buying interest is nudging momentum higher in the short term, even as longer term holders have seen weaker outcomes and may still be reassessing growth potential and risk.

If you are comparing BioMarin with other healthcare opportunities, this could be a useful moment to scan for niche leaders using the 39 healthcare AI stocks

With BioMarin’s share price weaker over 1 and 3 years, but recent revenue and net income growth on the board, plus a market value of about US$10.3b, is this a mispriced rare disease specialist or is future growth already reflected?

Most Popular Narrative: 39.2% Undervalued

BioMarin’s most followed narrative pegs fair value at $89.96 per share versus the last close at $54.66, framing a sizeable implied upside that hinges on a specific view of future growth and profitability.

Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.6) by about May 2029, up from $268.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.1 billion in earnings, and the most bearish expecting $746.2 million.

Curious what kind of revenue trajectory and margin profile would justify that jump in earnings, all discounted at 7.3% and paired with a lower future P/E multiple.

Result: Fair Value of $89.96 (UNDERVALUED)

However, there are clear pressure points, including heavier R&D and commercial spending, as well as tighter pricing or reimbursement decisions that could leave earnings and margins below consensus paths.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another lens on valuation

The popular fair value narrative leans on earnings forecasts and a future P/E, but the current numbers tell a tighter story. BioMarin trades on a P/E of 39.3x, versus 15.9x for the US biotech industry, 19.5x for peers and a fair ratio of 26x, which points to valuation risk rather than a clear bargain. How comfortable are you paying a premium multiple when growth, margins and execution are still being debated?

Next Steps

Feeling torn between the bullish fair value case and the premium P/E? This is the point to look under the hood yourself, weigh both the concern around risks and the optimism on potential rewards, and then decide how that balance sits with your own approach using these 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If BioMarin has sharpened your thinking, do not stop here. Broaden your watchlist and pressure test your approach against other stocks with different strengths.

• Target steadier compounding by scanning companies with resilient balance sheets and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for quality at a discount by checking companies that screen well on valuation and fundamentals through the 47 high quality undervalued stocks.
• Spot potential future standouts before the crowd by running the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.